F-star Therapeutics Announces Merck KGaA, Darmstadt, Germany Exercises a Fourth Licensing Option in Immuno-Oncology Collaboration Mari YoshiokaJanuary 5, 2022 Facebook0 Twitter LinkedIn0 Reddit 0 Likes